Skip to main content
OpenTrials
Completed

NCT Number: NCT01496131

Tecemotide (L-BLP25) in Prostate Cancer

This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Please Contact US Medical Information

Rockland, Massachusetts, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histopathologic documentation of prostate cancer confirmed at the institution of study enrollment prior to starting this study
  • Newly diagnosed or previously untreated prostate cancer with intermediate or high risk features as defined in the protocol
  • No evidence of metastatic disease on computed tomography (CT) / magnetic resonance imaging (MRI) or bone scans
  • No systemic steroid use within 2 weeks prior to initiation of experimental therapy. Limited doses of systemic steroids to prevent intravenous contrast, allergic reaction or anaphylaxis (in subjects who have known contrast allergies) are allowed
  • Eastern Co-operative Oncology Group (ECOG) performance status of 0-1
  • Human leukocyte antigen (HLA)-A2 or A3 positive for immunologic monitoring
  • Hematological and biochemical eligibility parameters as defined in the protocol
  • No other active malignancies within the past 3 years (with the exception of non-melanoma skin cancers or carcinoma in situ of the bladder)
  • Willing to travel to the study center(s) for follow-up visits
  • Age greater than or equal to 18 years old
  • Able to understand and sign informed consent
  • Must agree to use effective birth control (such as a condom) or abstinence during and for a period of 4 months after the last administration of immunotherapy

Exclusion criteria

  • No evidence of being immunocompromised by human immunodeficiency virus, a medical condition requiring systemic steroids, a medical condition requiring immunosuppressive therapy, splenectomy
  • Active Hepatitis B or Hepatitis C
  • Subjects should have no autoimmune diseases that have required treatment as specified in the protocol
  • History of immunodeficiency diseases, hereditary or congenital immunodeficiencies
  • Serious intercurrent medical illness
  • A clinically significant cardiac disease
  • Subjects who have received any prior therapy for prostate cancer
  • Subjects who have known brain metastasis, or with a history of seizures, encephalitis, or multiple sclerosis
  • Subjects receiving any other investigational agents
  • Contraindication to biopsy such as bleeding disorders, ratio of prothrombin time to partial thromboplastin time (PT/PTT) >=1.5 times the upper limit of normal, artificial heart valve
  • Contraindication to MRI such as subjects weighing >136 kilograms, allergy to magnetic resonance (MR) contrast agent, subjects with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices
  • Contraindication to radiation therapy such as pre-existing and active prostatitis or proctitis, inflammatory bowel disease or known genetic sensitivity to ionizing radiation, or history of prior radiation to the pelvis

Treatment and study plan

radiation therapy

Radiation

Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.

Goserelin

Drug

ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.

Cyclophosphamide

Drug

Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).

Tecemotide (L-BLP25)

Drug

Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.

Other names: L-BLP25, BLP25 liposome vaccine, Epipepimut-S

Primary outcomes

  1. Number of Subjects With Change From Baseline in the Mucinous Glycoprotein 1 (MUC1) Specific Systemic T-Cells Immune Response at Day 60 (Pre-Radiation)

    Time frame: Baseline and Day 60 (Pre-Radiation)

    MUC1-specific systemic immune response was measured by intracellular cytokine antigen specific staining following a period of in vitro stimulation (IVS) with overlapping 15-mer peptide pools encoding the tumor-associated antigen (TAA) MUC-1. Baseline was defined as the measurement taken prior to the first dose of study medication (Day 1).

  2. Number of Subjects With Change From Baseline in the Mucinous Glycoprotein 1 (MUC1) Specific Systemic T-Cells Immune Response at Day 190 (Post-radiation)

    Time frame: Baseline and Day 190 (Post-radiation)

    MUC1-specific systemic immune response was measured by intracellular cytokine antigen specific staining following a period of in vitro stimulation (IVS) with overlapping 15-mer peptide pools encoding the tumor-associated antigen (TAA) MUC-1. Baseline was defined as the measurement taken prior to the first dose of study medication (Day 1).

Secondary outcomes

  1. Number of Subjects With Progression/Recurrence Status Based on Prostate-specific Antigen (PSA) Levels

    Time frame: From randomization up to 24 months

    Progression/recurrence status was reported based on Prostate-specific Antigen (PSA) Levels. Recurrence of PSA after completion of therapy represents disease progression and was determined using the American Society for Therapeutic Radiology and Oncology (ASTRO) "Phoenix criteria". These criteria define biochemical recurrence after radiation therapy as a PSA level equal to the lowest (nadir) PSA level achieved after therapy plus 2 nanogram per milliliter.

  2. Number of Subjects With a Doubling in Number of T-cells in Tumor Biopsy From Baseline at Pre-radiotherapy (Pre-RT) and Post-radiotherapy (Post-RT)

    Time frame: Baseline, Week 6-12 (Pre-RT), Week 40 (Post-RT)

    Doubling in number of T-cells was assessed by immunologic responses (in the tumor microenvironment) in subjects consenting to undergo study biopsies. Baseline was defined as the measurement taken within 8 weeks of prior to the first dose of study medication (Day 1).

Sponsors and collaborators

Lead sponsor

EMD Serono

Industry

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Dec 21, 2011
Registry last updated
Mar 9, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.